Targeted Oncology3h
NKTR-255 Shows Promise for Reversing Radiation-Induced Lymphopenia in NSCLC
NKTR-255 in combination with durvalumab following chemoradiation was well-tolerated in patients with non–small cell lung ...
Targeted Oncology8h
The Targeted Pulse: A Review of Last Month’s FDA Prominent Actions and Key Data Updates Advancing Treatment Across Disease Types
October 2024, saw significant FDA actions and clinical trial updates that shaped cancer treatment progress. Highlights include acalabrutinib’s approval for mantle cell lymphoma, T-DXd’s priority ...